DK1397492T3 - Modificerede og stabiliserede GDF-propeptider og deres anvendelser - Google Patents
Modificerede og stabiliserede GDF-propeptider og deres anvendelserInfo
- Publication number
- DK1397492T3 DK1397492T3 DK02709366T DK02709366T DK1397492T3 DK 1397492 T3 DK1397492 T3 DK 1397492T3 DK 02709366 T DK02709366 T DK 02709366T DK 02709366 T DK02709366 T DK 02709366T DK 1397492 T3 DK1397492 T3 DK 1397492T3
- Authority
- DK
- Denmark
- Prior art keywords
- modified
- applications
- gdf propeptides
- stabilized gdf
- stabilized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26750901P | 2001-02-08 | 2001-02-08 | |
PCT/US2002/003467 WO2002068650A2 (en) | 2001-02-08 | 2002-02-08 | Modified and stabilized gdf propeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1397492T3 true DK1397492T3 (da) | 2007-07-09 |
Family
ID=23019083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02709366T DK1397492T3 (da) | 2001-02-08 | 2002-02-08 | Modificerede og stabiliserede GDF-propeptider og deres anvendelser |
Country Status (23)
Country | Link |
---|---|
US (6) | US7202210B2 (da) |
EP (1) | EP1397492B1 (da) |
JP (3) | JP4280071B2 (da) |
AR (1) | AR032567A1 (da) |
AT (1) | ATE357519T1 (da) |
AU (1) | AU2002243852B2 (da) |
BR (1) | BR0207110A (da) |
CA (2) | CA2437218A1 (da) |
CL (1) | CL2009000648A1 (da) |
CY (1) | CY1106629T1 (da) |
DE (1) | DE60219006T2 (da) |
DK (1) | DK1397492T3 (da) |
ES (1) | ES2284828T3 (da) |
HK (1) | HK1062457A1 (da) |
MX (1) | MXPA03007063A (da) |
NO (1) | NO333427B1 (da) |
NZ (2) | NZ527286A (da) |
PL (2) | PL212078B1 (da) |
PT (1) | PT1397492E (da) |
SG (2) | SG165982A1 (da) |
TW (2) | TW200526779A (da) |
WO (1) | WO2002068650A2 (da) |
ZA (2) | ZA200508954B (da) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
JP4429728B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン(follistatin)ドメイン含有タンパク質 |
AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
MXPA05002968A (es) * | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
WO2004083432A1 (en) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
RU2322261C2 (ru) * | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
EP2332977B1 (en) | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
EP1778275A2 (en) * | 2004-08-12 | 2007-05-02 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
EP1864138A2 (en) * | 2005-03-23 | 2007-12-12 | Wyeth | Detection of gdf-8 modulating agents |
CN101137906A (zh) * | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
DK1973559T3 (da) | 2005-11-23 | 2013-03-25 | Acceleron Pharma Inc | Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst |
US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
EP2502628B1 (en) * | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
CN103920139B (zh) * | 2007-02-01 | 2018-02-02 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI459963B (zh) | 2007-02-09 | 2014-11-11 | Acceleron Pharma Inc | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
NZ582521A (en) * | 2007-07-12 | 2011-09-30 | Prosensa Technologies Bv | A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue |
WO2009008725A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
CN107412734A (zh) * | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
DK2203173T3 (da) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Midler og fremgangsmåder til modvirkning af muskellidelser |
NZ587178A (en) * | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
MX2010012437A (es) | 2008-05-14 | 2011-06-01 | Agriculture Victoria Serv Pty | Uso de angiogenina o agonistas de angiogenina para tratar enfermedades y trastornos. |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
KR20190128002A (ko) * | 2008-06-26 | 2019-11-13 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
WO2010123369A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
EP2440576A4 (en) * | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES |
KR20210034684A (ko) | 2009-06-12 | 2021-03-30 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
KR20120062874A (ko) * | 2009-09-09 | 2012-06-14 | 악셀레론 파마 인코포레이티드 | ActRIIb 길항제들와 이의 투약 및 용도 |
US20110129469A1 (en) * | 2009-11-03 | 2011-06-02 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
TW201120210A (en) | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
CA2807607A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | Actriia結合剤およびその使用 |
EP2691421B1 (en) | 2011-03-31 | 2016-11-09 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
AU2012324495B2 (en) | 2011-10-21 | 2016-04-21 | Pfizer Inc. | Addition of iron to improve cell culture |
EP2802351B1 (en) | 2012-01-09 | 2019-03-27 | ADC Therapeutics SA | Agents for treating triple negative breast cancer |
CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
WO2014000042A1 (en) * | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
CA2880649C (en) | 2012-08-01 | 2023-03-14 | Elizabeth MCNALLY | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
ES2633960T3 (es) | 2012-10-15 | 2017-09-26 | Bristol-Myers Squibb Company | Procesos de cultivo de células de mamífero para la producción de proteínas |
CN112933223A (zh) | 2012-10-24 | 2021-06-11 | 细胞基因公司 | 用于治疗贫血的方法 |
CN113604550A (zh) * | 2012-10-24 | 2021-11-05 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
KR102279522B1 (ko) | 2012-11-02 | 2021-07-19 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
BR112015018104A2 (pt) | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
JP6143270B2 (ja) * | 2013-01-31 | 2017-06-07 | 学校法人東京薬科大学 | マイオスタチン阻害ペプチド |
WO2014168973A2 (en) | 2013-04-08 | 2014-10-16 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating skeletal muscle stem cells |
WO2014201143A1 (en) * | 2013-06-11 | 2014-12-18 | President And Fellows Of Harvard College | Methods and compositions for increasing neurogenesis and angiogenesis |
EP3027642B1 (en) * | 2013-07-31 | 2020-08-19 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
CN104725513A (zh) * | 2013-12-20 | 2015-06-24 | 中国科学院上海生命科学研究院 | 融合蛋白及其在治疗多发性硬化中的用途 |
EP3154566B1 (en) | 2014-06-13 | 2022-08-03 | Acceleron Pharma Inc. | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
PE20171058A1 (es) | 2014-10-31 | 2017-07-21 | Ngm Biopharmaceuticals Inc | Composiciones y metodos de uso para tratar trastornos metabolicos |
HUE062189T2 (hu) | 2014-12-03 | 2023-09-28 | Celgene Corp | Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére |
IL293766B2 (en) | 2016-01-06 | 2023-08-01 | Harvard College | Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis |
AU2017241161B2 (en) | 2016-03-31 | 2022-05-26 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
US20220143136A1 (en) | 2018-12-21 | 2022-05-12 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
CA1341617C (en) | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibin isolated from ovarian follicular fluid |
AU599572B2 (en) | 1984-07-06 | 1990-07-26 | Novartis Ag | Lymphokine production and purification |
EP0169016B2 (en) | 1984-07-16 | 2004-04-28 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
US4740587A (en) | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US4798885A (en) | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
US5215893A (en) | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
NZ217727A (en) | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
US4737578A (en) | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Factors that soak bone formation |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
WO1989010409A1 (en) | 1988-04-08 | 1989-11-02 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
US5071834A (en) | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
ATE162223T1 (de) | 1989-03-28 | 1998-01-15 | Genetics Inst | Osteoinduktive zusammensetzungen |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
CA2020729A1 (en) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
US5166190A (en) | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
DE69132823T2 (de) | 1990-05-16 | 2002-07-18 | Genetics Institute, Inc. | Knochen- und knorpel-bildung hervorrufende proteine |
ATE253589T1 (de) | 1990-09-26 | 2003-11-15 | Inst Genetics Llc | Bmp-5-derivate |
JP3356775B2 (ja) | 1990-11-30 | 2002-12-16 | セルトリックス ファーマシューティカルズ, インコーポレイテッド | TGF―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用 |
US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
CA2102808A1 (en) | 1991-05-10 | 1992-11-11 | Hanne Bentz | Targeted delivery of bone growth factors |
KR100255415B1 (ko) | 1991-06-25 | 2000-05-01 | 브루스 엠. 에이센 | 비엠피-9 조성물 |
AU661854B2 (en) * | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5171579A (en) | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
PT653942E (pt) | 1992-07-31 | 2003-11-28 | Curis Inc | Regeneracao e reparacao de nervos induzidos por morfogenios |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
EP2272959A1 (en) | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
ATE326234T1 (de) | 1993-08-26 | 2006-06-15 | Genetics Inst Llc | Menschliche knochen-morphogenetische proteine zur verwendung bei neuronaler regeneration |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
WO1996001845A1 (en) | 1994-07-08 | 1996-01-25 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
US5466190A (en) * | 1994-07-25 | 1995-11-14 | Deere & Company | Precleaner for a cleaning shoe |
US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
JPH10262688A (ja) * | 1994-11-30 | 1998-10-06 | Univ Rockefeller | 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途 |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
JP4847634B2 (ja) | 1996-03-22 | 2011-12-28 | ストライカー・コーポレーション | 中枢神経系の虚血または外傷の機能的回復を増大させる方法 |
US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
PE99498A1 (es) * | 1996-07-26 | 1999-01-21 | Novartis Ag | Polipeptidos de fusion |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
EP2045322B1 (en) * | 1997-07-14 | 2015-07-01 | Université de Liège | Double-muscling in mammals |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
GB2345397B (en) * | 1997-08-19 | 2001-10-31 | Citizen Watch Co Ltd | Piezoelectric vibrator |
CA2302525A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
AU1276399A (en) * | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
WO1999024618A1 (en) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
WO1999040181A1 (en) | 1998-02-05 | 1999-08-12 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
EP1075272B1 (en) | 1998-05-06 | 2009-07-15 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
WO2000011163A1 (en) | 1998-08-20 | 2000-03-02 | Regeneron Pharmaceuticals, Inc. | Dcr5, a bmp-binding protein, and applications thereof |
CN100567322C (zh) | 1999-01-21 | 2009-12-09 | 梅塔莫菲克斯公司 | 抑制生长分化因子活性的多肽及表达该多肽的细胞 |
CA2375700A1 (en) * | 1999-06-01 | 2000-12-07 | Biogen, Inc. | Polymer conjugates of hedgehog proteins and uses |
US7056512B1 (en) | 1999-07-20 | 2006-06-06 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
PL350983A1 (en) * | 2001-11-30 | 2003-06-02 | Advanced Digital Broadcast Ltd | Method of scanning a high-frequency signal band and apparatus therefor |
JP4429728B2 (ja) * | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン(follistatin)ドメイン含有タンパク質 |
AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
MXPA05002968A (es) * | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
DE60335915D1 (de) | 2002-12-20 | 2011-03-10 | Amgen Inc | Myostatin hemmende bindungsstoffe |
RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
CN101137906A (zh) | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
EP1864138A2 (en) | 2005-03-23 | 2007-12-12 | Wyeth | Detection of gdf-8 modulating agents |
-
2002
- 2002-02-07 TW TW094108366A patent/TW200526779A/zh unknown
- 2002-02-07 TW TW091102268A patent/TWI329129B/zh not_active IP Right Cessation
- 2002-02-08 AR ARP020100421A patent/AR032567A1/es not_active Application Discontinuation
- 2002-02-08 AT AT02709366T patent/ATE357519T1/de active
- 2002-02-08 PT PT02709366T patent/PT1397492E/pt unknown
- 2002-02-08 JP JP2002568744A patent/JP4280071B2/ja not_active Expired - Fee Related
- 2002-02-08 CA CA002437218A patent/CA2437218A1/en not_active Abandoned
- 2002-02-08 PL PL390369A patent/PL212078B1/pl unknown
- 2002-02-08 SG SG200506783-0A patent/SG165982A1/en unknown
- 2002-02-08 MX MXPA03007063A patent/MXPA03007063A/es active IP Right Grant
- 2002-02-08 SG SG2010040194A patent/SG187989A1/en unknown
- 2002-02-08 AU AU2002243852A patent/AU2002243852B2/en not_active Ceased
- 2002-02-08 CA CA002674673A patent/CA2674673A1/en not_active Abandoned
- 2002-02-08 BR BR0207110-0A patent/BR0207110A/pt not_active IP Right Cessation
- 2002-02-08 PL PL372888A patent/PL207202B1/pl unknown
- 2002-02-08 ZA ZA200508954A patent/ZA200508954B/en unknown
- 2002-02-08 ES ES02709366T patent/ES2284828T3/es not_active Expired - Lifetime
- 2002-02-08 NZ NZ527286A patent/NZ527286A/en not_active IP Right Cessation
- 2002-02-08 US US10/071,499 patent/US7202210B2/en not_active Expired - Fee Related
- 2002-02-08 EP EP02709366A patent/EP1397492B1/en not_active Expired - Lifetime
- 2002-02-08 WO PCT/US2002/003467 patent/WO2002068650A2/en active IP Right Grant
- 2002-02-08 NZ NZ550297A patent/NZ550297A/en not_active IP Right Cessation
- 2002-02-08 DK DK02709366T patent/DK1397492T3/da active
- 2002-02-08 DE DE60219006T patent/DE60219006T2/de not_active Expired - Lifetime
-
2003
- 2003-08-04 NO NO20033456A patent/NO333427B1/no not_active IP Right Cessation
- 2003-08-06 ZA ZA200306064A patent/ZA200306064B/en unknown
-
2004
- 2004-07-08 HK HK04104973A patent/HK1062457A1/xx not_active IP Right Cessation
-
2005
- 2005-07-19 JP JP2005209321A patent/JP2006001938A/ja not_active Withdrawn
-
2006
- 2006-12-21 US US11/614,702 patent/US7737116B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/614,594 patent/US7560441B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 CY CY20071100719T patent/CY1106629T1/el unknown
-
2008
- 2008-11-21 JP JP2008298812A patent/JP5013618B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-18 CL CL2009000648A patent/CL2009000648A1/es unknown
- 2009-05-04 US US12/434,758 patent/US8222384B2/en not_active Expired - Fee Related
-
2012
- 2012-06-14 US US13/523,391 patent/US8710025B2/en not_active Expired - Fee Related
-
2013
- 2013-09-19 US US14/032,079 patent/US20140228289A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1397492T3 (da) | Modificerede og stabiliserede GDF-propeptider og deres anvendelser | |
DK1572744T3 (da) | Immunoglobulinvarianter og deres anvendelser | |
DK1455785T3 (da) | Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse | |
DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
NO20042418L (no) | Anti-IL-6-antistoffer, sammensetninger, fremgangsmater og deres anvendelser | |
DK1498413T3 (da) | 4-aminopicolinater og deres anvendelse som herbicider | |
DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
PT1411764E (pt) | Cerca | |
DE60120514D1 (de) | Plektrum | |
DK1328475T3 (da) | Zeolitter og deres anvendelse | |
IS2523B (is) | Turn vindorkuvers | |
DE60117938D1 (de) | Vorspannen von Bauteilen | |
DE60318139D1 (de) | Isolator- und Anordnungskonfiguration | |
EE200300483A (et) | Uudsed ekspressioonivektorid ja nende rakendused | |
ATE395917T1 (de) | Kombination von docetaxel mit flavopiridol | |
DK1392670T3 (da) | Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater | |
DK1370276T3 (da) | Intracellulær kommunikations-lettende forbindelser og deres medicinske anvendelser | |
DE60219418D1 (de) | Silanylphenole und -naphthole | |
DE50110467D1 (de) | Staffelei | |
ATE354561T1 (de) | Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen | |
FI20011441A (fi) | Levitysjärjestely | |
ITMI20022425A1 (it) | Distanziatore e distanziale. | |
ITMI20011210A0 (it) | Corticosteroidi-21-glicolati e 21-acilglicolati | |
UA5753S (uk) | Правило будівельне прямокутне | |
UA5250S (uk) | Робочий стіл |